William Blair Has Positive Estimate for TERN FY2025 Earnings

Key Points

• William Blair has revised its FY2025 earnings estimate for Terns Pharmaceuticals to a loss of ($1.09) per share, up from a previous forecast of ($1.10).
• In the latest quarterly earnings report, Terns Pharmaceuticals reported a loss of ($0.26) per share, exceeding consensus estimates of ($0.28) by $0.02.
• Insider transactions indicate confidence in the company's future, with CEO Amy L. Burroughs and CFO Andrew Gengos significantly increasing their stock holdings in recent months.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Equities research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for Terns Pharmaceuticals in a report issued on Tuesday, August 5th. William Blair analyst A. Hsieh now forecasts that the company will earn ($1.09) per share for the year, up from their previous forecast of ($1.10). The consensus estimate for Terns Pharmaceuticals' current full-year earnings is ($1.19) per share. William Blair also issued estimates for Terns Pharmaceuticals' Q1 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.20) EPS and FY2027 earnings at ($1.41) EPS.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02.

A number of other equities analysts also recently commented on the company. BMO Capital Markets cut their price objective on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and issued a $20.00 price objective on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.63.

Terns Pharmaceuticals Trading Up 7.8%

Shares of Terns Pharmaceuticals stock traded up $0.44 during trading hours on Friday, reaching $6.08. The stock had a trading volume of 798,851 shares, compared to its average volume of 1,061,507. The firm has a 50 day simple moving average of $4.69 and a two-hundred day simple moving average of $3.79. The firm has a market capitalization of $532.06 million, a price-to-earnings ratio of -5.85 and a beta of -0.05. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $11.40.

Institutional Investors Weigh In On Terns Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Acorn Capital Advisors LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $10,921,000. Soleus Capital Management L.P. increased its holdings in Terns Pharmaceuticals by 30.8% during the 4th quarter. Soleus Capital Management L.P. now owns 8,142,500 shares of the company's stock worth $45,109,000 after purchasing an additional 1,918,956 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in Terns Pharmaceuticals by 44.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,751,506 shares of the company's stock worth $26,323,000 after purchasing an additional 1,461,680 shares during the last quarter. Nuveen LLC purchased a new stake in Terns Pharmaceuticals during the 1st quarter worth approximately $3,880,000. Finally, Norges Bank purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $4,706,000. 98.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Amy L. Burroughs bought 23,314 shares of the company's stock in a transaction that occurred on Wednesday, June 25th. The shares were acquired at an average cost of $3.87 per share, for a total transaction of $90,225.18. Following the acquisition, the chief executive officer owned 47,083 shares in the company, valued at $182,211.21. This represents a 98.09% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew Gengos bought 10,000 shares of the company's stock in a transaction that occurred on Friday, June 27th. The shares were bought at an average price of $3.93 per share, for a total transaction of $39,300.00. Following the completion of the acquisition, the chief financial officer owned 25,000 shares in the company, valued at approximately $98,250. This trade represents a 66.67% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 48,314 shares of company stock worth $186,575. Company insiders own 1.50% of the company's stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.